SignaCor Therapeutics
ST
SI
SignaCor Therapeutics
Clinical-stage drug development company advancing treatments for hypertrophic cardiomyopathy and cardiovascular health.
About
SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen's University Belfast. They are developing first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) that target underlying disease pathology to reverse heart damage and improve patient outcomes.
Key facts
At-a-glance profile data
- Headquarters
- Belfast, United Kingdom
- Founded
- 2024
- Total funding
- $315K (Seed)
- Business model
- B2B
Funding rounds
Add first review
Frequently asked
How much funding has SignaCor Therapeutics raised?
SignaCor Therapeutics has raised a total of $315K in funding. The most recent round on record is Seed.